Peloton shares soar on digital content partnership with Lululemon

Peloton shares soar on digital content partnership with Lululemon


Jen Van Santvoord rides her Peloton exercise bike at her home in San Anselmo, California.

Ezra Shaw | Getty Images

Peloton shares spiked Wednesday as the company announced a five-year partnership to develop digital fitness content for Lululemon.

The fitness company’s stock soared as much as 30% in extended trading.

Lululemon said it will stop selling the Studio Mirror device by the end of the year.

This is breaking news. Please check back for updates.



Source

WNBPA President Nneka Ogwumike says new CBA will have a major impact on players’ bank accounts
Business

WNBPA President Nneka Ogwumike says new CBA will have a major impact on players’ bank accounts

The Women’s National Basketball Player’s Association ratified the terms of a new collective bargaining agreement Monday, calling it “transformational” and “bigger than basketball.” The new CBA begins this season and runs through 2032. When asked her opinion of the most important outcome from the deal, WNBPA President Nneka Ogwumike had two words: “Bank accounts.” “Being […]

Read More
Toyota to invest  billion to increase U.S. production in Kentucky, Indiana plants
Business

Toyota to invest $1 billion to increase U.S. production in Kentucky, Indiana plants

Production of the Toyota Camry at the automaker’s plant in Georgetown, Kentucky. Courtesy Toyota Toyota Motor on Monday announced it would spend $1 billion at two U.S. plants as part of a plan to invest up to $10 billion domestically over the next five years. The new investments include $800 million at a plant in […]

Read More
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Business

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a Lyme disease vaccine candidate despite the shot failing a late-stage trial. Pfizer said the vaccine missed the trial’s statistical goal because not enough people in the study contracted Lyme disease to be confident in the results. Still, […]

Read More